The Department of Health and Social Care (DH) has “redetermined the NHS reimbursement prices for all strengths of Mounjaro dispensed from September to reflect the new higher list prices”, the negotiator announced.
Community Pharmacy England (CPE) today (August 27) revealed that it has “reached an agreement” with the DH for NHS branded and generic Mounjaro prescriptions to be “reimbursed at the increased UK list prices”.
Read more: BREAKING: Lilly hikes Mounjaro price to address ‘inconsistencies’
According to the negotiator, this is to “avoid pharmacy owners dispensing Mounjaro at a loss” following the manufacturer Eli Lilly’s announcement earlier this month that it will hike the drug’s price in the UK by up to 170% from September 1.
It noted that the redetermined reimbursement prices will apply to September prescriptions “even though the September 2025 drug tariff still shows the old list prices”.
“The new list prices will be updated in the October 2025 drug tariff,” it added.
Redetermined prices
This means that the updated reimbursement prices from September will be:
Read more: CPE ‘urgently seeking assurances’ over Mounjaro reimbursement
It comes after CPE last week said that it was “urgently seeking assurances” from the DH that NHS reimbursement for dispensing Mounjaro would reflect the “higher list prices”.
And following distress in the sector about the price hike’s impact on both pharmacies and patients, private services provider Pharmadoctor last week told C+D that its “partner pharmacies” will be able to charge patients “much less” as part of a Mounjaro rebate scheme.
Lilly previously stressed that it has “reached an agreement with the NHS to ensure continued supply and patient access” but the details of this agreement including pricing remain unclear.
